Study of Antichromatin Antibodies As A Marker of Lupus Activity and Lupus Nephritis. 2018

Fatma M Elsenosy, and Sabila G Mousa, and Nagwa A Mohamed, and Rehab H Mohamed
Department of Internal Medicine, Faculty of Medicine for girls, Al-Azhar University, Cairo, Egypt.

Systemic Lupus Erythematosus (SLE) is a chronic and potentially fatal autoimmune disorder characterized by the production of auto-antibodies that cause widespread tissue damage. Validate Antichromatin antibodies as a biomarker of renal involvement in SLE and how their titers correlate with systemic lupus activity measure (SLAM) index among a sample of Egyptian systemic lupus patients. The study was conducted on 60 patients diagnosed according to ACR criteria for diagnoses of SLE (Group I) and 25 age matched healthy controls (Group II). Group I was divided into 30 patients without nephritis group A 1 and 30 patients with nephritis group IB. (anti-dsDNA, Antinuclear antibodies ANA), rheumatoid factor (RF), Complement component C3, C4 and antichromatin antibodies were done for all patients and controls. Serum antichromatin antibodies were positive in all cases of SLE and negative in all control subjects and were higher in group1B than group IA also; there were significant positive correlation between antichromatin antibodies and SLAM score of disease activity and classes of nephropathy. In conclusion, measurement of antichromatin antibodies is a useful addition to the laboratory work up for diagnosis and monitoring of SLE and prediction of lupus nephritis.

UI MeSH Term Description Entries
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D008181 Lupus Nephritis Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982). Glomerulonephritis, Lupus,Lupus Glomerulonephritis,Nephritis, Lupus,Glomerulonephritides, Lupus,Lupus Glomerulonephritides,Lupus Nephritides,Nephritides, Lupus
D004534 Egypt A country in northern Africa, bordering the Mediterranean Sea, between Libya and the Gaza Strip, and the Red Sea north of Sudan, and includes the Asian Sinai Peninsula Its capital is Cairo. Arab Republic of Egypt,United Arab Republic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000974 Antibodies, Antinuclear Autoantibodies directed against various nuclear antigens including DNA, RNA, histones, acidic nuclear proteins, or complexes of these molecular elements. Antinuclear antibodies are found in systemic autoimmune diseases including systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, and mixed connective tissue disease. Anti-DNA Antibodies,Antibodies, Anti-DNA,Antinuclear Antibodies,Antinuclear Autoantibodies,Antinuclear Autoantibody,Antinuclear Factors,Antinuclear Antibody,Antinuclear Factor,Anti DNA Antibodies,Antibody, Antinuclear,Autoantibody, Antinuclear,Factor, Antinuclear
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control

Related Publications

Fatma M Elsenosy, and Sabila G Mousa, and Nagwa A Mohamed, and Rehab H Mohamed
August 2008, Clinical immunology (Orlando, Fla.),
Fatma M Elsenosy, and Sabila G Mousa, and Nagwa A Mohamed, and Rehab H Mohamed
April 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation,
Fatma M Elsenosy, and Sabila G Mousa, and Nagwa A Mohamed, and Rehab H Mohamed
January 2016, The Egyptian journal of immunology,
Fatma M Elsenosy, and Sabila G Mousa, and Nagwa A Mohamed, and Rehab H Mohamed
August 2007, Autoimmunity reviews,
Fatma M Elsenosy, and Sabila G Mousa, and Nagwa A Mohamed, and Rehab H Mohamed
July 2022, Clinical journal of the American Society of Nephrology : CJASN,
Fatma M Elsenosy, and Sabila G Mousa, and Nagwa A Mohamed, and Rehab H Mohamed
July 2006, Clinical rheumatology,
Fatma M Elsenosy, and Sabila G Mousa, and Nagwa A Mohamed, and Rehab H Mohamed
January 2012, Journal of biomedicine & biotechnology,
Fatma M Elsenosy, and Sabila G Mousa, and Nagwa A Mohamed, and Rehab H Mohamed
November 2008, Clinical rheumatology,
Fatma M Elsenosy, and Sabila G Mousa, and Nagwa A Mohamed, and Rehab H Mohamed
July 2012, Arthritis research & therapy,
Fatma M Elsenosy, and Sabila G Mousa, and Nagwa A Mohamed, and Rehab H Mohamed
July 2018, Scandinavian journal of clinical and laboratory investigation,
Copied contents to your clipboard!